12 research outputs found
Outcomes for 18 to 25-year-olds with borderline personality disorder in a dedicated young adult only DBT programme compared to a general adult DBT programme for all ages 18
Aim
Targeting young adults with borderline personality disorder (BPD) for treatment may carry significant social and clinical benefits. We aimed to evaluate a communityâbased Dialectical Behaviour Therapy (DBT) programme delivered exclusively to young adults with BPD.
Methods
We describe a naturally occurring nonâequivalent, quasiâexperimental comparison of outcomes for young adults (18â25âyears) with BPD following 1 year of treatment in either a young adult only DBT programme or a general adult DBT programme (18+ years). Twentyâfour young adults enrolled in a communityâbased young adult DBT programme open only to 18â to 25âyearâolds with BPD. Another 13 young adults, also 18â25âyears, enrolled in a general adult DBT programme open to all ages above 18âyears. Both treatment conditions offered all modes of standard DBT for 1 year. Participants completed a battery of selfâreport measures on mental health symptoms at baseline and again at treatment completion after 1 year. Discharge rates at 2 years postâtreatment completion were also recorded.
Results
Better outcomes were found on borderline symptom severity and general psychopathology among completers of young adult DBT, with a large effect size for treatment condition as well as greater clinically significant change. Discharge rates from mental health services 24âmonths later were also higher for completers of young adult DBT.
Conclusions
There may be advantages in delivering DBT to young adults in an ageâspecific programme, possibly due to group cohesion. Methodological limitations apply, such as small sample size and nonârandomization. Further controlled research is needed
Are treatment gains maintained? Long-term psychological interventions for bordeline personality disorder
Changes in mindfulness facets in a dialectical behaviour therapy skills training group program for borderline personality disorder
Effects of mindfulness training on the default mode network in borderline personality disorder
Individual participant data systematic reviews with meta-analyses of psychotherapies for borderline personality disorder
Š 2021 BMJ Publishing Group. All rights reserved.Introduction The heterogeneity in people with borderline personality disorder (BPD) and the range of specialised psychotherapies means that people with certain BPD characteristics might benefit more or less from different types of psychotherapy. Identifying moderating characteristics of individuals is a key to refine and tailor standard treatments so they match the specificities of the individual participant. The objective of this is to improve the quality of care and the individual outcomes. We will do so by performing three systematic reviews with meta-analyses of individual participant data (IPD). The aim of these reviews is to investigate potential predictors and moderating patient characteristics on treatment outcomes for patients with BPD. Methods and analysis We performed comprehensive searches in 22 databases and trial registries up to October 6th 2020. These will be updated with a top-up search up until June 2021. Our primary meta-analytic method will be the one-stage random-effects approach. To identify predictors, we will use the one-stage model that accounts for interaction between covariates and treatment allocation. Heterogeneity in case-mix will be assessed with a membership model based on a multinomial logistic regression where study membership is the outcome. A random-effects meta-analysis is chosen to account for expected levels of heterogeneity. Ethics and dissemination The statistical analyses will be conducted on anonymised data that have already been approved by the respective ethical committees that originally assessed the included trials. The three IPD reviews will be published in high-impact factor journals and their results will be presented at international conferences and national seminars. PROSPERO registration number CRD42021210688